List of Ximino drug patents

Ximino is owned by Journey.

Ximino contains Minocycline Hydrochloride.

Ximino has a total of 6 drug patents out of which 0 drug patents have expired.

Ximino was authorised for market use on 11 July, 2012.

Ximino is available in capsule, extended release;oral dosage forms.

Ximino can be used as treatment of acne, treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

The generics of Ximino are possible to be released after 02 April, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268804 JOURNEY Minocycline oral dosage forms for the treatment of acne
Jun, 2025

(2 years from now)

US7790705 JOURNEY Minocycline oral dosage forms for the treatment of acne
Jun, 2025

(2 years from now)

US8252776 JOURNEY Minocycline oral dosage forms for the treatment of acne
Jun, 2025

(2 years from now)

US7919483 JOURNEY Method for the treatment of acne
Mar, 2027

(3 years from now)

US7541347 JOURNEY Minocycline oral dosage forms for the treatment of acne
Apr, 2027

(4 years from now)

US7544373 JOURNEY Minocycline oral dosage forms for the treatment of acne
Apr, 2027

(4 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 11 July, 2012

Treatment: Treatment of acne; Treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

XIMINO family patents

23

United States

2

Japan

1

New Zealand

1

Australia

1

Norway

1

South Africa

1

Canada

1

China

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in